Audit: QRS - Topical Caffeine for Hair Regrowth

Audit conducted on 26/09/2026 04:37 using AI4L + evidence-mcp / Opus 5.5

Iterations

Summary

Items Count
Total 94
Passed 87
Failed 0
N/A 7
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Lede, protocol, time-to-effect, tiers, gates, markers and cadence all trace to ER lines 299-302, 334, 162-204, 220-256, 270-284, 351-371, 385-393.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Cautious phrasing kept (e.g., “Harms appear minimal”, “No established numeric target”).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening or softening found; interaction severities (Caution/Monitor/No harmful interaction) match ER lines 270-277.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications come from the ER avoid-list; interactions from the ER interaction list; tiers from Expected Benefits / Potential Risks.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 Only brand name is “Rogaine”, present in ER line 270 for the same fact; no PMIDs, NCTs or expert names.
1.6 The QRS does not introduce new attributions. 🟢 No new attributions.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢  
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms are either glossed (trichoscopy, phototrichogram, keratolytic, free T4) or verbatim ER labels/headings.
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 It DOES NOT address the reader directly 🟢  
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Lede frames caffeine as a low-cost add-on and flags the risk of delaying stronger treatment, matching ER Conclusion.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” wording.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 No colloquial terms in the document’s own voice.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings, gate headings, tier labels and column headers present unchanged.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All template spans present; marker_# and qualitative_item_# expanded to numbered instances.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 website spans and footer unchanged; only addressed spans populated or hidden.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No QRS section maps to an empty ER section; empty ER tiers are governed by 12.5/13.5.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol and interaction labels match ER bold labels verbatim (ER lines 270-277, 299-302).
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢  
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emojis.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Sections condensed (interaction rationales and mitigations stripped); nothing extended beyond the template layout.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration is quoted, and it contains a colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.9.25 matches QRS.md.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢  
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢  
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0926-0414 -> 09/26/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢  
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens “Topical caffeine, a low-cost cosmetic applied to the scalp … is used to slow hereditary pattern hair thinning”.
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.3 [at_a_glance] is no longer than 70 words 🟢 70 words (script count).
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each fact maps to ER Conclusion lines 387-393.
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢  
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All four ER avoid-list populations (ER lines 281-284) present.
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Rationale “in whom no trials have been conducted” stripped.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “until healed” and “before a dermatologist’s diagnosis” preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A No ranking notation in the ER contraindications.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Section populated; ER names populations to avoid.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 All eight ER interactions present; none duplicate a contraindication.
9.3 Individual [caution_items] are formatted as <li></li> 🟢  
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Mitigation sentences stripped; only severity and key fact kept.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Parenthetical example lists preserved verbatim.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A No ranking notation in the ER interactions.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 Section populated; ER lists interactions.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Rinse-off shampoo, leave-on liquid and add-on approach (ER lines 299-302).
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct actionable aspects exist.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 ER gives two time points (3 months shedding, 6 months structural; ER line 334); both used.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢  
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. 🟢 Third time cell left empty and hidden with display: none.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high hidden with display: none.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_high and risks_medium hidden with display: none.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢  
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All seven ER table biomarkers plus androgen testing and free T4 from the ER narrative listed.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢  

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢  
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five ER qualitative markers listed verbatim.

Issues 26/09/2026 04:37

Pass rate 100.00%. No issues found.

Issues 26/09/2026 04:33

  1. 4.2 — CYP1A2 label not verbatim: Line 555 changes the ER bold label “CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, oral contraceptives)” by inserting “drugs that slow the liver enzyme that breaks down caffeine;” inside the bold label.

Fixes 26/09/2026 04:33

  1. 4.2 — CYP1A2 label restored verbatim: Removed the inserted gloss so the bold label reads exactly “CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, oral contraceptives)” as in the ER.

Issues 26/09/2026 04:30

  1. 2.7 — Unexplained jargon in gates/monitoring: “CYP1A2 inhibitors” (line 555) and “Trichoscopy or phototrichogram density” (line 667) appear without the plain-language glosses the ER provides, and “methylisothiazolinone” (line 542) drops the ER’s “the preservative” gloss.

Fixes 26/09/2026 04:30

  1. 2.7 — Plain-language glosses added: Expanded “CYP1A2 inhibitors” to “(drugs that slow the liver enzyme that breaks down caffeine; …)”, renamed marker 7 to “Trichoscopy (magnified scalp examination) or phototrichogram (photographic hair count) density”, and restored “the preservative methylisothiazolinone” per the ER.

Issues 26/09/2026 04:28

  1. 1.1 — Unsupported “baseline only” claim: Line 681 [marker_8_target] states androgen testing is a “baseline test only”, but the ER Monitoring section (lines 351–353) never restricts androgen testing to baseline.
  2. 9.4 — Mitigation retained in interaction: Line 560 Microneedling item keeps the ER mitigation “(24-hour wait before leave-on caffeine)”, an elaboration not present in the ER bullet label, while all other items’ mitigations were stripped.

Fixes 26/09/2026 04:28

  1. 1.1 — Unsupported “baseline only” claim: Changed [marker_8_target] from “No target stated; baseline test only, in women with irregular cycles or acne” to “No target stated; baseline test in women with irregular cycles or acne”.
  2. 9.4 — Mitigation retained in interaction: Removed the mitigation parenthetical “(24-hour wait before leave-on caffeine)” from the Microneedling and scalp procedures interaction item.

Issues 26/09/2026 04:27

  1. 1.1 / 11.3 — Invented third time-to-effect cell: The ER names only two time-to-effect aspects (reduced shedding at 3 months, structural changes at 6 months), but time_3 (lines 505-511) presents “Stress-related shedding / 6 months”, which the ER gives only as the length of an uncontrolled study, not as an onset time; the unused set should be left empty and hidden.

Fixes 26/09/2026 04:27

  1. 1.1 / 11.3 — Invented third time-to-effect cell: Emptied the time_3 label, value and sub spans (“Stress-related shedding / 6 months / Uncontrolled caffeine-shampoo study in women”) and hid the cell with display: none, since the ER names only two time-to-effect aspects.

Issues 26/09/2026 04:23

  1. 14.2 — Free T4 biomarker missing: The ER Monitoring table names free T4 as a measurable biomarker to pair with TSH (ER line 358: “best paired with free T4”), but the QRS Monitoring table (lines 598-687) does not list it.

Fixes 26/09/2026 04:23

  1. 14.2 — Free T4 biomarker added: Added a Monitoring row (marker_9) for “Free T4 (main circulating thyroid hormone)” with target “No target stated; paired with TSH” and why “Thyroid dysfunction causes diffuse shedding”, per ER line 358.

Issues 26/09/2026 04:20

  1. 1.4 — Timing shown as Target: Monitoring row 8 (line 681) puts “Baseline, in women with irregular cycles or acne” in the Target column for androgen testing; this is a baseline-timing/population fact from the ER Monitoring narrative (ER line 351), and the ER states no target for androgen testing.

Fixes 26/09/2026 04:20

  1. 1.4 — Timing shown as Target: Changed the androgen-testing Target cell (marker_8_target) from “Baseline, in women with irregular cycles or acne” to “No target stated; baseline test only, in women with irregular cycles or acne”, so the column no longer implies a target the ER does not give.

Issues 26/09/2026 04:17

  1. 1.1 — Unsupported “earliest change” claim: [time_1_sub] (line 489) reads “Earliest change seen in trials”, but the ER only states that reduced shedding “appeared at 3 months … in trials” and never calls it the earliest change.
  2. 2.7 — Unexplained “non-inferiority trial” jargon: [action_2_sub] (line 461) uses “non-inferiority trial” without explanation, although the ER offers the plain equivalent “the main trial”.

Fixes 26/09/2026 04:17

  1. 1.1 — Unsupported “earliest change” claim: Changed [time_1_sub] from “Earliest change seen in trials” to “Seen in trials”, matching the ER wording.
  2. 2.7 — Unexplained trial jargon: Changed [action_2_sub] from “in the non-inferiority trial” to “in the main trial”, the ER’s own plain phrasing.